Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.45 |
| ▸ | MTOR | P42345 | 7/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910047 | 0.89 | PIK3CA (0.49) | HRH4CKS1BSKP1SKP2PIK3CA | |
| SCHEMBL909555 | 0.83 | PIK3CA (0.69) | PIK3CAMTORPIK3R1PARP1BRAF | |
| SCHEMBL907946 | 0.80 | PIK3CA (0.46) | HRH4CKS1BSKP1SKP2PIK3CA | |
| SCHEMBL6523142 | 0.78 | PRKCI (0.45) | CKS1BSKP1SKP2PIK3CAMTOR | |
| SCHEMBL910184 | 0.78 | PIK3CA (0.47) | PIK3CAMTORPIK3R1PARP1BRAF | |
| SCHEMBL910089 | 0.74 | PIK3CA (0.71) | PIK3CAMTORPIK3R1PARP1PIK3CD | |
| SCHEMBL2440200 | 0.73 | PIK3CA (0.62) | PIK3CAMTORPIK3R1PARP1BRAF | |
| SCHEMBL6522275 | 0.72 | PIK3CD (0.64) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL21876102 | 0.72 | CKS1B (0.49) | CKS1BSKP1SKP2 | |
| SCHEMBL1309474 | 0.72 | PIK3CA (0.73) | PIK3CAMTORPIK3R1HTTPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | claimed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | claimed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | claimed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | HRH4 4003/4885CKS1B 402/4885SKP1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.